- Latest news▼
-
19:41, April 25 Children’s Hospital Los Angeles and International Center of Professional Development Allergy/Immunology Conference
-
17:31, April 25 JAMA: patient grew long, curly eyelashes because of chemotherapy
-
11:08, April 25 Mpox epidemic declared in Republic of the Congo
-
08:31, April 25 OU: quitting smoking 4 times more likely to cure laryngeal cancer
-
01:20, April 25 Paralyzed man in China writes hieroglyphs using neural implants placed in his brain
-
15:11, April 24 Zombie deer disease possibly linked to hunters’ deaths
-
12:27, April 23 Appetite: Scientists found out the secret to the appeal of large portions of fast food
-
10:33, April 23 Scientists test new approach to fighting viruses
-
08:38, April 23 Ketamine may help with postpartum depression
-
22:12, April 22 Unhealthy amount of sugar found in baby food products of a well-known brand
-
19:41, April 22 Air pollution puts health of more than 1.6 billion workers globally at risk
-
17:25, April 22 Scientists found baked goods and lack of sleep to be more dangerous than alcohol
-
16:02, April 22 342 cases of measles recorded in Armenia so far in 2024
-
15:29, April 22 BrainStimulation: electrical brain stimulation alleviates anxiety and depression in the elderly
-
08:27, April 22 Cognitively stimulating jobs in midlife could lower dementia risk in old age, study finds
All materials
FDA approves new drug to prevent malaria relapse
Researchers in the United States have approved a “new” drug for treating recurring malaria.
The drug, called tafenoquine is the first such anti-malarial drug to be given a clean bill of health in over 60 years.
The approval by the Food and Drug Administration (FDA) of the United States is seen as a shot in the arm for the fight against recurring malaria.
Once it is allowed to sell in drug stores around the world, tafenoquine is expected to significantly reduce deaths from recurrent malaria.
Caused by plasmodium vivax, recurring malaria affects 8.5 million people around the world every year.
Over the years this type of malaria has been difficult to combat due to the virus’ uncanny ability to remain inactive in the human liver for years before regenerating and causing infections.
Full article: https://www.nation.co.ke/news/Tafenoquine-malaria-drug-approved/1056-4677932-x8ew9bz/index.html
Follow NEWS.am Medicine on Facebook and Twitter
- Video
- Event calendar
- Children’s Hospital Los Angeles and International Center of Professional Development Allergy/Immunology Conference
- First Armenian-German Conference entitled “Heart Failure Spring School”
- Allogeneic bone marrow transplant in case of hematological malignancy performed in Armenia for first time
All materials
- Archive
- Most read
month
week
day
- JAMA Oncology: Urine test can help rule out high-grade prostate cancer with almost 100% accuracy, study shows 1297
- Scientists grow human mini-lungs in lab 1175
- Next pandemic likely to be triggered by flu - scientists 946
- Scientists found baked goods and lack of sleep to be more dangerous than alcohol 927
- 342 cases of measles recorded in Armenia so far in 2024 881
- Scientists develop new method to safely stimulate immune cells to fight cancer 785
- Blood test can determine who is at risk of developing multiple sclerosis - scientists 781
- Cognitively stimulating jobs in midlife could lower dementia risk in old age, study finds 781
- BrainStimulation: electrical brain stimulation alleviates anxiety and depression in the elderly 721
- Ketamine may help with postpartum depression 664
- Unhealthy amount of sugar found in baby food products of a well-known brand 659
- Appetite: Scientists found out the secret to the appeal of large portions of fast food 655
- Air pollution puts health of more than 1.6 billion workers globally at risk 654
- Scientists test new approach to fighting viruses 639
- Zombie deer disease possibly linked to hunters’ deaths 548
- Find us on Facebook
- Poll